A phase 1, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic human papillomavirus (HPV) DNA vaccine (AMV002) for HPV-associated head and neck cancer (HNC)

Chandra, J., Woo, W. P., Finlayson, N., Liu, H. Y., McGrath, M., Ladwa, R., Brauer, M., Xu, Y., Hanson, S., Panizza, B., Frazer, I. H. and Porceddu, S. V.  A phase 1, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic human papillomavirus (HPV) DNA vaccine (AMV002)…

Read More

Novel tumor suppressor role of miRNA-876 in cholangiocarcinoma

Ursu, S., Majid, S., Garger, C., de Semir, D., Bezrookove, V., Desprez, P., McAllister, S., Soroceanu, L., Nosrati, M., Yimam, K., Hassoun, A., Osorio, R., Kashani-Sabet, M., Dar, A. A.  Novel tumor suppressor role of miRNA-876 in cholangiocarcinoma.  Oncogenesis. 2019; 8(8), 42.  doi:10.1038/s41389-019-0153-z

Read More

SV-BR-1-GM, A Clinically Effective GM-CSF-Secreting Breast Cancer Cell Line, Expresses An Immune Signature And Directly Activates CD4+ T Lymphocytes

Lacher, M. D., Bauer, G., Fury, B., Graeve, S., Fledderman, E. L., Petrie, T. D., Coleal-Bergum, D. P., Hackett, T., Perotti, N. H., Kong, Y. Y., Kwok, W. W., Wagner, J. P., Wiseman, C. L., Williams, W. V. SV-BR-1-GM, A Clinically Effective GM-CSF-Secreting Breast Cancer Cell Line, Expresses An Immune Signature And Directly Activates CD4+…

Read More

Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA–Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy

Hung, C., Xu, X., Li, L., Ma, Y., Jin, Q., Viley, A., Allen, C., Natarajan, P., Shivakumar, R., Peshwa, M. V. and Emens, L. A. Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA–Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy. Human Gene Therapy. 2018; 29(5), 614-625. doi:10.1089/hum.2017.080

Read More